BioMed Research International / 2015 / Article / Tab 2

Research Article

Hypoglycaemia, Abnormal Lipids, and Cardiovascular Disease among Chinese with Type 2 Diabetes

Table 2

Odds ratio of abnormal lipids for mild and severe hypoglycaemia.

Mild hypoglycaemiaSevere hypoglycaemiaEither mild or severe hypoglycaemia
OR (95% CI) valueOR (95% CI) valueOR (95% CI) value

Model one
 LDL-C, mmol/L1.12 (1.00–1.26)0.05261.22 (1.05–1.43)0.01391.14 (1.03–1.26)0.0109
 HDL-C, mmol/L1.12 (1.00–1.26)0.05261.22 (1.05–1.43)0.01391.14 (1.03–1.26)0.0109
 Triglyceride, mmol/L 1.12 (1.05–1.19)0.00021.02 (0.87–1.19)0.79881.10 (1.05–1.17)0.0005
Model two
 LDL-C, mmol/L1.14 (1.01–1.29)0.03311.21 (1.04–1.17)0.01631.15 (1.03–1.28)0.0110
 HDL-C, mmol/L1.10 (1.04–1.17)0.00151.01 (0.87–1.17)0.89221.09 (1.03–1.16)0.0049
 Triglyceride, mmol/L 0.96 (0.86–1.07)0.46641.10 (0.94–1.28)0.23130.98 (0.89–1.09)0.7388
Model three
 LDL-C, mmol/L1.14 (1.01–1.29)0.03401.24 (1.05–1.48)0.01291.17 (1.04–1.31)0.0079
 HDL-C, mmol/L1.10 (1.03–1.17)0.00301.02 (0.83–1.24)0.88601.09 (1.02–1.16)0.0084
 Triglyceride, mmol/L 0.92 (0.82–1.04)0.18581.02 (0.82–1.26)0.89160.93 (0.83–1.04)0.2238

Model one: not adjusted for other variables.
Model two: adjusted for age, sex, BMI, HbA1c, systolic BP, and log-transformed urinary albumin to creatinine ratio.
Model three: further adjusted for diabetes complications (coronary artery disease, stroke, and peripheral arterial disease) and drug use (statins, other lipid lowering drugs, rennin-angiotensin system inhibitors, oral antidiabetes drugs only, glucagon-like peptide-1 based treatment, basal insulin based treatment, and premixed insulin based treatment).

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.